Longqiang Guo, Degang Tao, Bing Chen, Hui Zhu, Fei Wang
{"title":"Effect of Alendronate Sodium Combined with Alpha-Calciferol on Chronic Obstructive Pulmonary Disease with Osteoporosis","authors":"Longqiang Guo, Degang Tao, Bing Chen, Hui Zhu, Fei Wang","doi":"10.36468/pharmaceutical-sciences.spl.676","DOIUrl":null,"url":null,"abstract":"We attempt to explore and study the effect of alendronate sodium combined with alpha-calciferol on chronic obstructive pulmonary disease patients with osteoporosis treatment and the changes of serum receptor activator for nuclear factor kappa B ligand and osteoprotegerin levels. We randomly selected 56 patients in the hospital from December 2021 to December 2022 as the study subjects. According to the time of admission, we divided them into two parts. 28 patients were given routine treatment as the control group and the other 28 patients were given alendronate sodium combined with alpha-calciferol as the observation group. Evaluate and compare both groups on the clinical efficacy rate and measure the serum receptor activator for nuclear factor kappa B ligand level and osteoprotegerin level after taking the fasting venous blood of the patients. The adverse reactions occurred during the treatment were counted and adverse reactions rate was calculated. The results showed that observation group had higher clinical control ratio and effective ratio than control group. In addition, observation group possessed higher clinical efficacy efficiency value of the patients than control group and the improvement was more obvious (p<0.05). In terms of serum level results, observation group had better data values of patients than control group. The serum receptor activator for nuclear factor kappa B ligand level, osteoprotegerin level, forced vital capacity 1 level and forced vital capacity 1/forced vital capacity values of patients in observation group were significantly improved than those in control group (p<0.05). In terms of adverse reaction evaluation, observation group during treatment had lower adverse reactions rate than control group (p<0.05). Alendronate sodium combined with alpha-calciferol can improve the clinical efficacy of chronic obstructive pulmonary disease and osteoporosis patients to a certain extent, and have a better effect on serum receptor activator for nuclear factor kappa B ligand, osteoprotegerin level and lung function.","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":null,"pages":null},"PeriodicalIF":0.4000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Pharmaceutical Sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.36468/pharmaceutical-sciences.spl.676","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
We attempt to explore and study the effect of alendronate sodium combined with alpha-calciferol on chronic obstructive pulmonary disease patients with osteoporosis treatment and the changes of serum receptor activator for nuclear factor kappa B ligand and osteoprotegerin levels. We randomly selected 56 patients in the hospital from December 2021 to December 2022 as the study subjects. According to the time of admission, we divided them into two parts. 28 patients were given routine treatment as the control group and the other 28 patients were given alendronate sodium combined with alpha-calciferol as the observation group. Evaluate and compare both groups on the clinical efficacy rate and measure the serum receptor activator for nuclear factor kappa B ligand level and osteoprotegerin level after taking the fasting venous blood of the patients. The adverse reactions occurred during the treatment were counted and adverse reactions rate was calculated. The results showed that observation group had higher clinical control ratio and effective ratio than control group. In addition, observation group possessed higher clinical efficacy efficiency value of the patients than control group and the improvement was more obvious (p<0.05). In terms of serum level results, observation group had better data values of patients than control group. The serum receptor activator for nuclear factor kappa B ligand level, osteoprotegerin level, forced vital capacity 1 level and forced vital capacity 1/forced vital capacity values of patients in observation group were significantly improved than those in control group (p<0.05). In terms of adverse reaction evaluation, observation group during treatment had lower adverse reactions rate than control group (p<0.05). Alendronate sodium combined with alpha-calciferol can improve the clinical efficacy of chronic obstructive pulmonary disease and osteoporosis patients to a certain extent, and have a better effect on serum receptor activator for nuclear factor kappa B ligand, osteoprotegerin level and lung function.
期刊介绍:
The Indian Journal of Pharmaceutical Sciences (IJPS) is a bi-monthly Journal, which publishes original research work that contributes significantly to further the scientific knowledge in Pharmaceutical Sciences (Pharmaceutical Technology, Pharmaceutics, Biopharmaceutics, Pharmacokinetics, Pharmaceutical/Medicinal Chemistry, Computational Chemistry and Molecular Drug Design, Pharmacognosy and Phytochemistry, Pharmacology and Therapeutics, Pharmaceutical Analysis, Pharmacy Practice, Clinical and Hospital Pharmacy, Pharmacovigilance, Pharmacoepidemiology, Pharmacoeconomics, Drug Information, Patient Counselling, Adverse Drug Reactions Monitoring, Medication Errors, Medication Optimization, Medication Therapy Management, Cell Biology, Genomics and Proteomics, Pharmacogenomics, Bioinformatics and Biotechnology of Pharmaceutical Interest). The Journal publishes original research work either as a Full Research Paper or as a Short Communication. Review Articles on current topics in Pharmaceutical Sciences are also considered for publication by the Journal.